ArticleBrain imaging and behavior2025
Altered effective connectivity within the hippocampal-prefrontal circuit in patients with non-small cell lung cancer after platinum chemotherapy.
Article in Brain imaging and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To investigate the effects of platinum-based chemotherapeutic drugs on the effective connectivity (EC) of hippocampal-prefrontal (HIP-PFC) circuit in non-small cell lung cancer (NSCLC) patients utilizing spectral dynamic causal model (sDCM), and to explore its correlation with cognitive deficits. A total of 109 patients diagnosed with NSCLC (57 without chemotherapy (CT-) and 52 with chemotherapy (CT+)) and 60 healthy controls (HCs) were enrolled. Longitudinal data pre- and post-chemotherapy were available for 30 patients. All participants underwent functional magnetic resonance imaging (fMRI) and cognitive assessments. Effective connectivity within the HIP-PFC circuit for all participants were analyzed using the sDCM approach. Relationships between abnormal connectivity strength and neuropsychological scores were evaluated. The results revealed ECs differences among three groups in the HIP-PFC circuit concentrated in the bilateral hippocampus and right frontal lobe. Analysis of paired groups identified more abnormalities across cerebral hemispheres, including excitatory connectivity from l-HIP to right lateral prefrontal cortex (LPFC). The reduced EC from the l-HIP to the medial prefrontal cortex (mPFC) was significantly negatively correlated with the MoCA scores (r = -0.315, p = 0.007), and the reduced EC from the r-HIP to the mPFC was significantly negatively correlated with the memory scores (r = -0.349, p = 0.006). These insights further bolstered the crucial role of the HIP-PFC circuit in the pathophysiology of cognitive impairment induced by platinum-based chemotherapeutic agents, highlighting its potential as a novel imaging biomarker and therapeutic target.
Indexed as
Identifiers
41017011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.